Tag Archives: Germany

In COVID-19 clampdown, China bars travelers from Britain, France, India

BEIJING (Reuters) – China has barred non-Chinese travelers from Britain, France, Belgium, the Philippines and India, imposing some of the most stringent entry curbs of any country as coronavirus cases surge around the world.

The restrictions, which cover those with valid visas and residence permits and take effect in conjunction with a more restrictive testing regime for arrivals from several other countries, drew a frosty response from Britain.

“We are concerned by the abruptness of the announcement and the blanket ban on entry, and await further clarification on when it will be lifted,” said the British Chamber of Commerce in China as the blanket bans were announced by the five countries’ Chinese embassies.

England started a month-long lockdown on Thursday. Britain’s virus death toll is the highest in Europe, and it is grappling with more than 20,000 new cases a day.

Belgium has Europe’s highest per capita number of new confirmed cases, while France and India are among the top five countries in the world with the most infections.

The suspensions were a partial reversal of an easing on Sept. 28, when China allowed all foreigners with valid residence permits to enter. In March, China had banned entry of foreigners in response to the epidemic.

‘SOLD OUT IN SECONDS’

Meanwhile, many people planning November visits to China scrambled to book earlier flights to circumvent potentially disruptive restrictions due to come into force for other countries from Friday.

Linyi Li, a Chinese national, had planned to fly from Seattle to China in mid-November but switched her flight to Nov. 6 even though fares had tripled.

“The tickets were sold out in seconds, as people were all scrambling to beat the deadline,” said Li, 30. “I’ve been rushing to sell many of my family belongings in the past days in case I can’t get back to the States.”

From Friday, all passengers from the United States, France, Germany and Thailand bound for mainland China must take a nucleic acid test and a blood test for antibodies against the coronavirus no more than 48 hours before boarding.

Flights scheduled for Friday are not covered by the new rule, since passengers would have done their tests before that day under previous requirements.

China also plans to impose dual-test requirements on travelers from Australia, Singapore and Japan from Nov. 8.

The European Union Chamber of Commerce in China said the antibody test was not widely available in many countries.

“(So) unfortunately, while technically leaving the door open, these changes imply a de facto ban on anyone trying to get back to their lives, work and families in China,” said the European Union Chamber of Commerce in China.

On Tuesday, China Southern Airlines, the country’s biggest carrier by passenger load, said it would suspend transit services for passengers embarking from 21 countries, mostly African and Asian countries and including India and the Philippines.

The number of weekly international passenger flights serving mainland China from late October through March is set to slump 96.8% from a year earlier to 592, the latest schedules show.

(Reporting by Ryan Woo, Lusha Zhang, Dominique Patton, Stella Qiu, Gabriel Crossley, Martin Pollard and Shivani Singh; Editing by Jacqueline Wong and John Stonestreet)

Countries turn to rapid antigen tests to contain second wave of COVID-19

By John Miller, Caroline Copley and Bart H. Meijer

ZURICH/BERLIN (Reuters) – Countries straining to contain a second wave of COVID-19 are turning to faster, cheaper but less accurate tests to avoid the delays and shortages that have plagued efforts to diagnose and trace those infected quickly.

Germany, where infections jumped by 4,122 on Tuesday to 329,453 total, has secured 9 million so-called antigen tests per month that can deliver a result in minutes and cost about 5 euros ($5.90) each. That would, in theory, cover more than 10% of the population.

The United States and Canada are also buying millions of tests, as is Italy, whose recent tender for 5 million tests attracted offers from 35 companies. Switzerland, where new COVID-19 cases are at record levels, is considering adding the tests to its nationwide screening strategy.

Germany’s Robert Koch Institute (RKI) now recommends antigen tests to complement existing molecular PCR tests, which have become the standard for assessing active infections but which have also suffered shortages as the pandemic overwhelmed laboratories and outstripped manufacturers’ production capacity.

PCR tests detect genetic material in the virus while antigen tests detect proteins on the virus’s surface, though both are meant to pick up active infections. Another type of test, for antibodies the body produces in response to an infection, can help tell if somebody has had COVID-19 in the past.

Like PCR (polymerase chain reaction) tests, antigen tests require an uncomfortable nasal swab. They can also produce more “false negatives,” prompting some experts to recommend they only be used in a pinch.

Still, the alarming rise in new infections globally has health officials desperately pursuing more options as the winter influenza season looms.

The World Health Organization reported more than 2 million new cases last week, bringing the total worldwide to 37 million, with more than 1 million deaths from COVID-19.

“These point-of-care tests could make a big difference,” said Gerard Krause, epidemiology department director at Germany’s Helmholtz Centre for Infection Research.

NO TEST NO FLIGHT

Krause said low-priority patients – those without symptoms – could initially be screened with antigen tests, leaving the more accurate PCR tests for those showing signs of the disease.

Antigen tests have already gained traction in the travel industry. Italian airline Alitalia offers Rome-Milan flights exclusively for passengers with negative tests and Germany’s Lufthansa has announced similar testing plans.

But the pandemic’s vast scale has strained the ability of countries to test all of their citizens, making it difficult to track the twisting paths of infection comprehensively and prevent a resurgence.

In the United States, for example, reliance on automated PCR machinery over the summer left many patients frustrated as they waited for a week or more for results.

Testing in Europe has also suffered glitches.

France does over a million tests a week but its free-for-all testing policy has led to long queues and delays in results, prompting French researchers to come up with a test they say can produce results in 40 minutes, without using a swab.

Italy does between 800,000 and 840,000 tests a week, more than double April’s levels, according to the Ministry of Health. But a government adviser, University of Padua microbiology professor Andrea Crisanti, said the country needs 2 million tests a week to really get on top of the virus.

In the Netherlands, where infection rates are among Europe’s highest, the government has been scrambling to expand weekly testing and lab capacity to 385,000 by next week from 280,000 now. The target is nearly half a million tests a week by December and just under 600,000 by February.

But people have been waiting days for a test. The authorities blame the overwhelming demand from those without clear symptoms for clogging up the system.

In response, the authorities have restricted rapid antigen tests to health workers and teachers, while others go on a waiting list.

‘GOLD STANDARD’

The various hitches highlight a conundrum for governments: how to get people back to work while tracing the virus within the population quickly – without running out of supplies.

Siemens Healthineers, which on Wednesday announced the launch of a rapid antigen test kit in Europe that can deliver a result in 15 minutes, said the volumes of such diagnostic tests being circulated globally now are “at the limits” of what manufacturers can supply.

Rivals including Abbott Laboratories and Becton Dickinson also offer numerous COVID-19 diagnostic tests, with more and more companies jumping in.

Swiss diagnostics maker Roche, announced plans on Tuesday to launch a new antigen test by the end of the year. Its fully automated systems can provide a test result in 18 minutes and a single lab machine can process 300 tests an hour.

By early 2021, the Basel-based company said it could make some 50 million of the new tests a month, on top of the rapid point-of-care tests it already sells.

Roche said the test could be deployed in places such as nursing homes or hospitals, where speedy results could thwart a potentially lethal outbreak.

“The primary use case is the testing of symptomatic patients,” a Roche spokeswoman said. “The secondary use case is the testing of individuals suspected of infection … which could also include asymptomatic patients.”

Expert opinion, however, on just how to use antigen tests is evolving and remains the subject of debate.

Switzerland, where reported new infections spiked to 2,823 cases on Wednesday from as low as three per day in June, is only now validating the accuracy of the rapid tests.

“Deployment of the rapid tests – where it makes sense – will be integrated into our testing strategy,” a spokesman for the Swiss federal health ministry said. “We’ll update our testing recommendations in November.”

Sandra Ciesek, director of the Institute of Medical Virology at the University Clinic in Frankfurt, Germany said rapid antigen tests could be an option for asymptomatic patients planning to visit elderly patients at nursing homes.

But people should refrain from using them as a definitive substitute to judge their infection status.

“The PCR test remains the gold standard,” Ciesek said. “An antigen test should only be used as an alternative if PCR is not possible in a timely manner.”

(Reporting by John Miller in Zurich, Caroline Copley in Berlin, Emilio Parodi and Giselda Vagnoni in Milan, Josephine Mason in London, Bart Meijer in Amsterdam and Matthias Blamont in Paris; Editing by David Clarke)

Europeans, UK tell U.N. Navalny poisoning a ‘threat to international peace, security’

By Michelle Nichols

NEW YORK (Reuters) – The poisoning of Kremlin critic Alexei Navalny “constitutes a threat to international peace and security,” Britain, France, Germany, Estonia and Belgium wrote in a letter to the United Nations Security Council, seen by Reuters on Thursday.

“We call on the Russian Federation to disclose, urgently, fully and in a transparent manner, the circumstances of this attack and to inform the Security Council in this regard,” they said in the letter sent to the 15-member body late on Wednesday.

Navalny was flown to Berlin in August after falling ill on a Russian domestic flight. He received treatment for what Germany said was poisoning by a potentially deadly nerve agent, Novichok, before being discharged in September.

The letter to the Security Council said that on Sept. 2 the German government confirmed that tests had shown “unequivocal proof that Mr Navalny had been poisoned by a chemical nerve agent from the Novichok group, which was developed by the Soviet Union and subsequently held by its successor state” Russia.

Russia has denied any involvement in the incident and said it has yet to see evidence of a crime. The Russian mission to the United Nations did not have an immediate comment on the letter.

The European members of the Security Council and Britain noted that last November the Security Council adopted a statement reaffirming that any use of chemical weapons “anywhere, at any time, by anyone, under any circumstance is unacceptable and a threat to international peace and security.”

“As such, we consider that the use of a chemical nerve agent from the Novichok group in the abhorrent poisoning of Mr Alexey Navalny constitutes a threat to international peace and security,” they wrote.

The letter was sent as Russia takes the monthly presidency of the Security Council for October.

The United States did not sign the letter, but on Wednesday U.S. Secretary of State Mike Pompeo said: “The Russian Government must provide a full accounting for the poisoning of Alexei Navalny and hold those involved responsible.”

(Reporting by Michelle Nichols; editing by Jonathan Oatis)

Height of fashion? Clothes mountains build up as recycling breaks down

By Sonya Dowsett and George Obulutsa

MADRID/NAIROBI (Reuters) – Clothes recycling is the pressure-release valve of fast fashion, and it’s breaking under COVID-19 curbs.

The multi-billion-dollar trade in second-hand clothing helps prevent the global fashion industry’s growing pile of waste going straight to landfill, while keeping wardrobes clear for next season’s designs. But it’s facing a crisis.

Exporters are struggling, as are traders and customers in often poorer nations from Africa to Eastern Europe and Latin America who rely on a steady supply of used clothes.

The signs are everywhere.

From London to Los Angeles, many thrift shops and clothing banks outside stores and on streets have been deluged with more clothes than could be sold on, leading to mountains of garments building up in sorting warehouses.

Since the COVID-19 pandemic began early this year, textile recyclers and exporters have had to cut their prices to shift stock as lockdown measures restrict movement and business slows in end markets abroad. For many, it’s no longer commercially viable and they can’t afford to move merchandise.

“We are reaching the point where our warehouses are completely full,” Antonio de Carvalho, boss of a textile recycling company in Stourbridge, central England, wrote to a client in June, asking for a price cut for clothes he collects.

De Carvalho pays towns for clothing collected in his containers then sells it on at profit to traders overseas.

Since May, he said, the price he has been able to charge overseas buyers had dropped from 570 pounds ($726) a tonne to 400 pounds, making it hard for his company, Green World Recycling, to cover the costs of collecting and storing items.

Buyers were also asking to increase the credit periods before they had to pay from 15 days to 45-60 days, adding to cash-flow problems, de Carvalho wrote.

“We are losing … a huge amount of money, making a big loss for the operation.”

‘GOING OUT OF BUSINESS’

De Carvalho’s experience is mirrored across the sector, suggesting that, even once the pandemic passes, the battered trade could take a long time to recover.

Recyclers are removing clothes banks from streets, reducing the number of times they are emptied per week and looking at laying off workers to conserve cash, according to Reuters interviews with 16 market players in Britain, the United States, Germany and the Netherlands.

At the same time, in a bleak irony for such firms, donations have mounted as people stuck at home clear out their wardrobes – a boon in normal times.

“This is unlike any other recession in a century,” said Jackie King, executive director of U.S. trade body the Secondary Materials and Recycled Textiles Association (SMART). “I would anticipate there will be companies going out of business.”

The retreat of recyclers is having far-reaching consequences for an industry that has seen an annual average of more than $4 billion of used clothing exported globally over the five years to 2019, according to U.N. trade data.

Exports have shrunk this year.

In Britain, the weight of used clothing exported from March to July was around half what it was for the same period last year, official trade data shows. Exports improved in July – the latest month on record – as merchants rushed to shift stock as countries began to re-open, but were still down around 30%.

In the United States, the value of exports from March to July fell 45% compared with the same period last year, government data shows.

Up to a third of clothes donated in the United States – the world’s biggest exporter of used clothing – ends up for sale in markets in the developing world.

KENYAN WOES

The consequences of the decline can be seen in countries like Kenya, which imported 176,000 tonnes of second-hand clothing in 2018, equivalent to over 335 million pairs of jeans.

Business is sluggish in the open-air Gikomba market in Nairobi, one of the biggest second-hand clothes market in East Africa. Shop assistants stand idle while traders call out to shoppers asking them to try their garments

Traders have been hit with a double-whammy of the shrinking supply, exacerbated by the government banning the import of used textiles in March on concerns they could carry the novel coronavirus, and a drop in footfall due to people staying home.

“Before coronavirus came in, I would manage to sell at least 50 (pairs of) trousers a day,” said trader Nicholas Mutisya, who sells jeans and hats. “But now with coronavirus, even selling one a day has become difficult.”

“We cannot buy bales (of clothes) directly, so we buy our stock from those who have already bought them.”

The ban on used textiles imports was lifted in August after pushback from traders in Kenya and industry bodies in Europe and the United States who said second-hand clothes were safe as the virus could not survive the journey to Africa.

Yet the struggle continues for traders like Mutisya and Anthony Kang’ethe, who works as a driver for a shop selling second-hand clothes in bales shipped from Britain. He said the business had been hit hard by the supply crunch.

“Before we used to have five workers in our company,” Kang’ethe said. “We are left with two.”

DARK SIDE OF FASHION

Large-scale commercial trade in second-hand clothing from Europe and the United States to emerging markets took off in a big way in the 1990s due to growing African and Eastern European demand for Western fashion.

Such demand has provided a badly needed release value for a booming fashion market, where clothing production has approximately doubled over the past 15 years, according to sustainability charity the Ellen MacArthur Foundation.

The fashion industry is the second-biggest consumer of water and is responsible for up to 10% of global carbon emissions – more than all international flights and maritime shipping combined, the U.N.’s environment program said in March 2019.

Meanwhile, clothes account for a massive, and growing, pile of waste that ends up in landfills.

In Britain, shoppers buy more clothes per person than any other country in Europe, amounting to some five times more than what they bought in the 1980s, according to a 2019 UK parliamentary report by the Environmental Audit Committee.

About 300,000 tonnes of clothing goes to landfill or incineration per year, the report said.

The United States produces just under 17 million U.S. tons (15.4 tonnes) of textile waste per year, according to the Environmental Protection Agency – equivalent to around 29 billion pairs of jeans. Two-thirds of this ends up in landfills.

Many fashion retailers, including Zara owner Inditex and H&M, encourage shoppers to bring unwanted textiles to their stores for collection and, in the case of H&M, even offer discounts on new purchases in exchange.

Only a small proportion of clothes collected by Inditex end up for sale in international markets, a company spokesman said. H&M said clothing collected in its stores was processed by I:CO, a unit of German textile recycling company Soex.

“The whole problem is just getting bigger,” said Anna Smith, a doctoral researcher at King’s College London looking at a so-called circular economic system, which aims to eliminate waste.

“People are consuming more and more.”

(Additional reporting by Lisa Baertlein in Los Angeles and Anna Ringstrom in Stockholm; Editing by Pravin Char)

U.S. pension funds sue Allianz after $4 billion in coronavirus losses

By Tom Sims

FRANKFURT (Reuters) – Pension funds for truckers, teachers and subway workers have lodged lawsuits in the United States against Germany’s Allianz, one of the world’s top asset managers, for failing to safeguard their investments during the coronavirus market meltdown.

Market panic around the virus that resulted in billions in losses earlier this year scarred many investors, but no other top-tier asset manager is facing such a large number of lawsuits in the United States connected to the turbulence.

In March, Allianz was forced to shutter two private hedge funds after severe losses, prompting the wave of litigation the company says is “legally and factually flawed”.

Together, the various suits filed in the U.S. Southern District of New York claim investors lost a total of around $4 billion. The fallout has also prompted questions from the U.S. Securities and Exchange Commission, Allianz has said.

A spokesman for Allianz Global Investors said in a statement to Reuters: “While the losses were disappointing, the allegations made by claimants are legally and factually flawed, and we will defend ourselves vigorously against them.”

The plaintiffs are professional investors who bought funds that “involved risks commensurate with those higher returns,” the spokesman added.

The latest claims against Allianz and its asset management arm Allianz Global Investors last week include one from the pension fund for the operator of New York’s transport system, the Metropolitan Transportation Authority (MTA). It has 70,000 employees and made an initial investment of $200 million.

Similar suits have been filed against Allianz by pension funds for the Teamster labor union, Blue Cross and Blue Shield, and Arkansas teachers. The suits are seeking a jury trial to award damages.

The suits allege that Allianz Global Investors, in its Structured Alpha family of funds, strayed from a strategy of using options to protect against a short-term financial market crash.

The SEC’s inquiry continues and Allianz is cooperating. The SEC did not respond to requests for comment.

Attracting investors with an “all-weather” investing approach, Allianz “bet the house” and “out of greed … sacrificed the hard-earned pension and benefits of the MTA’s workers, who at the time were risking their lives under COVID keeping New York alive,” the MTA’s lawsuit said.

The cases are a second front of litigation for Allianz, one of Europe’s largest insurance companies. The Munich-based company and its competitors face suits for not paying claims related to business closures during the pandemic lockdowns.

The company’s insurance business as a whole has been under pressure as it faces claims for cancelled events, and a decline in demand for car and travel insurance. It expects to post the first decline in annual profit in nearly a decade.

At the end of March, Allianz informed investors it was liquidating two funds, as well as an offshore feeder fund. Investors lost 97% on one of the funds, the suits say.

In April, Morningstar downgraded its rating for the remaining funds to negative “because of the failure in risk management protocols and the uncertainty”.

Allianz disputed that rating and in July published an internal report that found that the losses “were not the result of any failure in the portfolio’s investment strategy or risk management processes”.

(Reporting by Tom Sims; editing by David Evans)

Germans fear Trump more than coronavirus, survey shows

BERLIN (Reuters) – Germans are more afraid of the policies of U.S. President Donald Trump than of the coronavirus which has wreaked havoc on Europe’s biggest economy, an annual survey of German attitudes showed on Thursday.

Fears that Trump’s policies would make the world a more dangerous place eclipsed economic worries, with 53% of those asked putting him top of their list, according to the survey conducted in June and July for the R+V Insurance Group.

Rising living costs, the economic situation and the cost to taxpayers of European Union debt came second, third and fourth for traditionally cautious Germans.

The coronavirus took 17th spot and only around a third of those asked said they were concerned that they or someone they knew well would get COVID-19.

Germany has kept the number of COVID-19 cases and deaths relatively low compared with some of its European neighbors, but new infections are rising again.

The survey did not give details on which aspects of Trump’s policies worried Germans but R+V quoted political scientist Manfred Schmidt of the Ruprecht-Karls-University in Heidelberg as blaming his foreign policy.

“Particularly notable are the trade-war-like conflicts with China and trade and security policy attacks against allies, including Germany. In addition, the withdrawal of the United States from international cooperation and the confrontation with Iran,” said Schmidt who advises R+V on the annual survey.

Some 2,400 people were questioned for the “Fears of Germans” survey, which has been conducted since 1992.

(Reporting by Madeline Chambers, editing by Emma Thomasson and Catherine Evans)

U.S. House members ask Trump to probe Navalny poisoning, suggest sanctions

WASHINGTON (Reuters) – The Republican and Democratic leaders of the U.S. House of Representatives Foreign Affairs Committee called on President Donald Trump’s administration on Tuesday to investigate the suspected poisoning of Russian opposition leader Alexei Navalny, suggesting sanctions might be necessary.

“If the Russian government is once again determined to have used a chemical weapon against one of its own nationals, additional sanctions should be imposed,” Representatives Eliot Engel, the Democratic committee chairman, and Michael McCaul, the panel’s top Republican, said in a letter to Trump.

Germany, where Navalny is in a hospital, has said Navalny was poisoned with a Soviet-style Novichok nerve agent and wants the perpetrators held to account. Russia has until now not opened a criminal investigation and said there is no evidence yet of a crime.

Navalny is the most popular and prominent opponent of President Vladimir Putin, and the German announcement that he was poisoned by a nerve agent has raised the possibility of further Western sanctions against Moscow.

The White House did not immediately respond to a request for comment on the letter. Trump said on Friday his administration had not yet seen proof that Navalny was poisoned.

(Reporting by Patricia Zengerle; Editing by Alistair Bell)

WHO’s Tedros says ‘vaccine nationalism’ would prolong pandemic

By Stephanie Nebehay and Emma Farge

GENEVA (Reuters) – WHO Director-General Tedros Adhanom Ghebreyesus said on Friday that “vaccine nationalism” would only slow the effort to quash the pandemic and called for vaccines to be used fairly and effectively.

Tedros said 78 high-income countries had now joined the “COVAX” global vaccine allocation plan, bringing the total to 170 countries, and the “number is growing”. He urged others to join by the Sept. 18 deadline for binding commitments.

Joining the plan guaranteed those countries access to the world’s largest portfolio of vaccines, with nine candidates currently in the pipeline, he said, adding that a further four were “promising”.

The WHO and the GAVI vaccine alliance are leading the COVAX facility, aimed at helping buy and distribute vaccination shots fairly around the world.

But some countries that have secured their own supplies through bilateral deals, including the United States, have said they will not join COVAX.

“Vaccine nationalism will prolong the pandemic, not shorten it,” Tedros told a WHO briefing in Geneva, without mentioning any specific countries.

“If and when we have an effective vaccine, we must also use it effectively … In other words, the first priority must be to vaccinate some people in all countries, rather than all people in some countries,” he said, adding that priority should be given to healthcare workers, the elderly and those with underlying conditions.

Tedros thanked Germany, Japan, Norway and the European Commission for joining COVAX during the last week.

“Certainly by the middle of 2021 we should start to see some vaccines actually moving into countries and populations,” said WHO chief scientist Soumya Swaminathan, reiterating earlier comments.

Noting that there were 13 experimental vaccines currently in clinical trails, Swaminathan called it an “optimistic scenario” since the typical success rate of 10% could mean several vaccines are approved.

But Swaminathan said that no vaccine should be approved for a worldwide rollout until it had undergone sufficient scrutiny.

“No vaccine is going to be mass-deployed until regulators are confident, governments are confident, and the WHO is confident it has met the minimum standard of safety and efficacy,” she said.

Results were expected from some of the candidates already in phase 3 trials, each involving thousands of participants, by the end of the year or early 2021, Swaminathan said.

“We are not going to have enough for the whole world right at the beginning,” she said adding that scaling up of manufacturing would take time.

“Eventually there will be enough for everyone but it will mean prioritization,” she said.

(Reporting by Stephanie Nebehay and Emma Farge; Editing by Alison Williams and Giles Elgood)

U.S. troops to start extended exercises in Lithuania amid tensions over Belarus

By Andrius Sytas

VILNIUS (Reuters) – U.S. troops and tanks will arrive in Lithuania on Friday for a two-month deployment near the Belarus border, but the government said the move was not a message to its Russian-backed neighbor, where protests continue over a disputed election.

In an announcement on Wednesday evening, NATO member Lithuania said U.S. troops will be moved from Poland for pre-planned military exercises. These are “defensive in nature and not directed against any neighbor, including Belarus,” it added.

However, the troops are arriving earlier and staying longer than the government had indicated before the outbreak of protests in Belarus over the Aug. 9 election that returned President Alexander Lukashenko, a key ally of Russian leader Vladimir Putin, to power.

Lukashenko has denied accusations by the Belarus opposition and Western countries that the vote was rigged and has resisted protesters’ demands to step down. He has accused NATO of a military buildup near Belarus’ borders, something the alliance denied, and has said he will ask for Russian military help if needed.

The deployment in Lithuania, which will begin on Friday and will last until November, includes 500 American troops and 40 vehicles, such as Abrams tanks and Bradley armored troop carriers, a Lithuanian army spokesman said.

On July 29, Lithuanian Defense Minister Raimundas Karoblis told BNS wire the United States would send a battalion-sized troop contingent – between 300 to 1,000 soldiers – in September, for two weeks’ training, beginning in the middle of the month.

He repeated that information on Aug. 4 in an interview with public radio LRT.

“Deployment was aligned with training schedule and training area availability,” defense minister spokeswoman Vita Ramanauskaite told Reuters.

In addition to the U.S. deployment, up to 1,000 troops and military planes from France, Italy, Germany, Poland and others will take part in an annual exercise on Sept. 14-25, the Lithuanian army spokesman said.

The ministry did not state any plans for those troops to stay beyond Sept. 25.

Karoblis said earlier this month that there was a real danger Russia would send forces to Belarus.

(Reporting by Andrius Sytas; Editing by Simon Johnson, Steve Orlofsky and Frances Kerry)

Exclusive: Vaccine group says 76 rich countries now committed to ‘COVAX’ access plan

By Kate Kelland

LONDON (Reuters) – Seventy-six wealthy nations are now committed to joining a global COVID-19 vaccine allocation plan co-led by the World Health Organization (WHO) that aims to help buy and fairly distribute the shots, the project’s co-lead said on Wednesday.

Seth Berkley, chief executive of the GAVI vaccines alliance, said the plan, known as COVAX, now has Japan, Germany, Norway and more than 70 other nations signed up, agreeing in principle to procure COVID-19 vaccines through the facility for their populations.

“We have, as of right now, 76 upper middle income and high income countries that have submitted confirmations of intent to participate – and we expect that number to go up,” Berkley told Reuters in an interview.

“This is good news. It shows that the COVAX facility is open for business and is attracting the type of interest across the world we had hoped it would.”. COVAX coordinators are in talks with China about whether it might also join, Berkley said.

“We had a discussion yesterday with the (Chinese) government. We don’t have any signed agreement with them yet,” but Beijing had given “a positive signal”.

Chinese Foreign Ministry spokeswoman Hua Chunying told a briefing on Wednesday that China “supports COVAX and has been in communication with WHO and other parties” about it.

COVAX is co-led by GAVI, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI). It is designed to discourage national governments from hoarding COVID-19 vaccines and to focus on first vaccinating the most high-risk people in every country.

Its backers say this strategy should lead to lower vaccine costs for everyone and a swifter end to the pandemic that has claimed some 860,000 lives globally.

Wealthy countries that join COVAX will finance the vaccine purchases from their national budgets, and will partner with 92 poorer nations supported through voluntary donations to the plan to ensure vaccines are delivered equitably, Berkley said.

Participating wealthy countries are also free to procure vaccines through bilateral deals and other plans.

The United States said on Tuesday it would not join COVAX due to the Trump administration’s objection to WHO involvement, a move described by some critics as “disappointing.” Berkley said he was not surprised by the U.S. decision, but would seek to continue talks with Washington.

In what appeared to be a change of position on Wednesday, the European Union said its member states could buy potential COVID-19 vaccines through COVAX.

COVAX coordinators sought to add flexibility to joining agreements to encourage greater participation, Berkley said.

The WHO describes COVAX as an “invaluable insurance policy” for all countries to secure access to safe and effective COVID-19 vaccines when they are developed and approved. The plan’s coordinators have set a deadline of Sept. 18 for countries signing up to make binding commitments.

Asked to comment on the U.S. decision not to join COVAX, and on talks with China, a WHO spokesperson said: “Countries have until Sept. 18 to sign binding agreements…, so we’ll have more to say on countries that have joined then.”

COVAX’s objective is to procure and deliver 2 billion doses of approved vaccines by the end of 2021. It currently has nine COVID-19 vaccine candidates in its portfolio employing a range of different technologies and scientific approaches.

A handful are already in late-stage clinical trials and could have data available by year end.

(Reporting by Kate Kelland; Additional reporting by Stephanie Nebehay in Geneva and Yew Lun Tian in Beijing; Editing by Bill Berkrot and Mark Heinrich)